OYST News and Press, Oyster Point Pharma Inc. From 05/11/20

Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash Equivalents of $128.6 million as of March 31, 2020 Conference Call and Webcast S...

PRINCETON, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced tha...

Gainers: RTIX   +50.0% .   QTNT   +19.6% . SNDX   +17.3% . PI   +9.2% . More news on: RTI Surgical Holdings, Inc., Quotient Limited, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020              NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) --  Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stag...

Today, we will see why Oyster Point Pharma ( OYST ) is an attractive investment opportunity in 2020. Company overview Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments targeting ocular surface disea...

Image source: The Motley Fool. Oyster Point Pharma (NASDAQ: OYST) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading

Oyster Point Pharma (NASDAQ: OYST ): GAAP EPS of -$1.41 misses by $0.75 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm ET PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinic...

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jef...